home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Genetic News | search  
 

Research Shows Existing Diabetes Drugs May Kill Multiple Myeloma

 
  December, 20 2004 12:21
your information resource in human molecular genetics
 
     
In laboratory tests on multiple myeloma cells, University of Rochester researchers found that this type of cancer expresses a protein that makes it an easy target for an existing class of diabetes drugs. After more investigation, they hope the discovery will lead to a new, targeted therapy for myeloma patients.

"To our knowledge, this is the first time anyone has shown that multiple myeloma cells are sensitive to these agents, and we found multiple myeloma cells are killed quite effectively," says lead author Richard P. Phipps, Ph.D., professor of Environmental Medicine and of Oncology at the University of Rochester Medical Center.

The research was reported in the November issue of Clinical Immunology.

The drugs in question are from the thiazolidinedione (TZD) class of anti-diabetic therapies, known as PPAR-gamma ligands. They bind to PPAR-gamma, a protein associated with multiple myeloma and many other cancers, as well as chronic inflammation and diabetes. When the drugs bind to PPAR-gamma, at least in laboratory experiments, the cancerous cells are destroyed.

PPAR-ligands are emerging as a new type of cancer therapy because they directly target errant cells and stop tumor growth, at least in animal models. Phipps' laboratory also found that the PPAR-ligands currently used in anti-diabetic drugs could induce a type of cell death called apoptosis. This is significant because multiple myeloma is very difficult to treat, as it is usually resistant to drug-induced apoptosis.

Another encouraging factor is that the anti-diabetes drugs were able to kill the multiple myeloma cells, despite the fact that myeloma produces its own growth factor (Interleukin 6), which usually enables the cancer to multiply more effectively. Furthermore, the Phipps lab found that the effectiveness of the TZD drugs was enhanced when combined with Vitamin A-like compounds.

Co-investigator Steven Bernstein, M.D., who treats myeloma patients at the University's James P. Wilmot Cancer Center, is cautious but hopeful about the prospects of this research leading to a new treatment. "Although we are optimistic about these early findings, we need to do further investigation to understand how the TZD class of drugs work against multiple myeloma, before clinical trials are warranted."

Each year doctors diagnose about 14,000 people in the United States with multiple myeloma, which accounts for about 10 percent of the blood cancers. Myeloma is characterized by an abnormal number of white blood cells called plasma cells. They crowd out healthy blood cells in the bone marrow, and make proteins that lead to bone destruction, kidney damage, and recurrent infections.

High-dose chemotherapy and stem-cell transplant are the standard treatments. Recently, patients have also experienced some success with two new, biologically targeted therapies: thalidomide, which was given decades ago to women for morning sickness, and the proteosome inhibitor Velcade, which targets the parts of the cell that regulates protein expression, Bernstein said. The latest research may offer a third novel approach.

The myeloma research emerged from a larger investigation conducted by Phipps' laboratory into inflammation, the culprit of many serious illnesses. One area of focus is how the immune system reacts to PPAR-ligands.

© 2004· University of Rochester


Ray DM, Bernstein SH, Phipps RP.
Human multiple myeloma cells express peroxisome proliferator-activated receptor gamma and undergo apoptosis upon exposure to PPARgamma ligands.
Clin Immunol. 2004 Nov;113(2):203-13.


Message posted by: Frank S. Zollmann

print this article mail this article
Bookmark and Share this page (what is this?)

Social bookmarking allows users to save and categorise a personal collection of bookmarks and share them with others. This is different to using your own browser bookmarks which are available using the menus within your web browser.

Use the links below to share this article on the social bookmarking site of your choice.

Read more about social bookmarking at Wikipedia - Social Bookmarking

Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2016 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.